0000950170-23-069761.txt : 20231212
0000950170-23-069761.hdr.sgml : 20231212
20231212164337
ACCESSION NUMBER: 0000950170-23-069761
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231208
FILED AS OF DATE: 20231212
DATE AS OF CHANGE: 20231212
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: White William Richard
CENTRAL INDEX KEY: 0001778739
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38944
FILM NUMBER: 231481749
MAIL ADDRESS:
STREET 1: C/O AKERO THERAPEUTICS, INC.
STREET 2: 170 HARBOR WAY 2ND FLOOR
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Akero Therapeutics, Inc.
CENTRAL INDEX KEY: 0001744659
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 601 GATEWAY BOULEVARD, SUITE 350
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-487-6488
MAIL ADDRESS:
STREET 1: 601 GATEWAY BOULEVARD, SUITE 350
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
ownership.xml
4
X0508
4
2023-12-08
0001744659
Akero Therapeutics, Inc.
AKRO
0001778739
White William Richard
C/O AKERO THERAPEUTICS, INC.
601 GATEWAY BOULEVARD, SUITE 350
SOUTH SAN FRANCISCO
CA
94080
false
true
false
false
Chief Financial Officer
false
Common Stock
2023-12-08
4
A
false
32497
0.00
A
50965
D
Stock Option (Right to Buy)
19.87
2023-12-08
4
A
false
146237
0.00
A
2033-12-07
Common Stock
146237
146237
D
These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in eight (8) equal semi-annual installments, commencing from December 8, 2023, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
This option shall vest and become exercisable in forty-eight (48) equal monthly installments, commencing from December 8, 2023, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
/s/ Jonathan Young, Attorney-in-Fact
2023-12-12